Kim SH, Chun HJ, Choi HS, Kim ES, Keum B, Jeen YT. Current status of intragastric balloon for obesity treatment. World J Gastroenterol 2016; 22(24): 5495-5504 [PMID: 27350727 DOI: 10.3748/wjg.v22.i24.5495]
Corresponding Author of This Article
Hoon Jai Chun, MD, PhD, AGAF, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Institute of Gastrointestinal Medical Instrument Research, Korea University College of Medicine, 126-1, Anam-dong 5 ga, Seongbuk-gu, Seoul 02841, South Korea. martin.tobi@va.gov
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Jun 28, 2016; 22(24): 5495-5504 Published online Jun 28, 2016. doi: 10.3748/wjg.v22.i24.5495
Current status of intragastric balloon for obesity treatment
Seung Han Kim, Hoon Jai Chun, Hyuk Soon Choi, Eun Sun Kim, Bora Keum, Yoon Tae Jeen
Seung Han Kim, Hoon Jai Chun, Hyuk Soon Choi, Eun Sun Kim, Bora Keum, Yoon Tae Jeen, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Institute of Gastrointestinal Medical Instrument Research, Korea University College of Medicine, Seoul 02841, South Korea
Author contributions: Kim SH and Chun HJ designed the study; Kim ES and Jeen YT assisted in creating the tables and figures; Choi HS and Keum B analyzed the data; and Kim SH wrote the manuscript.
Supported by Korea Health Technology R and D Project through the Korea Health Industry Development Institute; and Ministry of Health and Welfare, South Korea, No. HI14C3477.
Conflict-of-interest statement: Seung Han Kim, Hoon Jai Chun, Hyuk Soon Choi, Eun Sun Kim, Bora Keum and Yoon Tae Jeen have no conflicts of interest or financial ties to disclose.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Hoon Jai Chun, MD, PhD, AGAF, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Institute of Gastrointestinal Medical Instrument Research, Korea University College of Medicine, 126-1, Anam-dong 5 ga, Seongbuk-gu, Seoul 02841, South Korea. martin.tobi@va.gov
Telephone: +82-2-9206555 Fax: +82-2-9531943
Received: March 27, 2016 Peer-review started: March 28, 2016 First decision: April 14, 2016 Revised: April 28, 2016 Accepted: May 21, 2016 Article in press: May 23, 2016 Published online: June 28, 2016 Processing time: 85 Days and 21.9 Hours
Abstract
Endoscopic bariatric therapy may be a useful alternative to pharmacological treatment for obesity, and it provides greater efficacy with lower risks than do conventional surgical procedures. Among the various endoscopic treatments for obesity, the intragastric balloon is associated with significant efficacy in body weight reduction and relief of comorbid disease symptoms. Anatomically, this treatment is based on gastric space-occupying effects that increase the feeling of satiety and may also affect gut neuroendocrine signaling. The simplicity of the intragastric balloon procedure may account for its widespread role in obesity treatment and its applicability to various degrees of obesity. However, advances in device properties and procedural techniques are still needed in order to improve its safety and cost-effectiveness. Furthermore, verification of the physiological outcomes of intragastric balloon treatment and the clinical predictive factors for treatment responses should be considered. In this article, we discuss the types, efficacy, safety, and future directions of intragastric balloon treatment.
Core tip: Obesity is a complex metabolic illness that is associated with several comorbid diseases. There has been a constant demand for safe and more effective weight reduction interventions to fill the gap in the treatment of obesity. The intragastric balloon is a fascinating intermediate alternative solution between medical obesity treatment and bariatric surgical procedures for obese patients that may provide better efficacy and have a more favorable risk profile.
